Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2009-09-18 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming to present at UBS Global Life Sciences Conference
Regulatory Filings Classification · 85% confidence The document is a short press release announcing that the company, Pharming Group NV, will be presenting at an external industry event, the UBS Global Life Sciences Conference. It specifies the date, time, and location of the presentation and mentions that a webcast will be available. This type of announcement, which informs investors about participation in a conference or roadshow, is best classified as an Investor Presentation (IP) if it were the presentation itself, but since this is the *announcement* of participation, and it is a brief press release, it fits best under the general category for regulatory/investor communications that aren't specific financial reports or mandatory filings. However, given the context of presenting to investors, it is a form of investor communication. Since there is no specific category for 'Conference Presentation Announcement,' and it is not a formal regulatory filing (RNS) or a detailed presentation (IP), I must check the definitions. It is not an ER, 10-K, or IR. It is an announcement about an upcoming investor event. The closest fit among the provided options that covers investor-facing activities outside of formal reporting is often captured by general investor communications. Given the content is about presenting business updates to investors, 'Investor Presentation (IP)' might be considered if the document *was* the presentation slides, but as a short announcement, 'Regulatory Filings (RNS)' serves as the best general category for non-standard, timely investor news releases that don't fit elsewhere, or potentially 'Report Publication Announcement (RPA)' if it were announcing the publication of a report, which it is not. Since this is a proactive announcement about engaging with investors at a conference, and it is very short (2100 chars), it is a timely communication. I will classify this as a Regulatory Filing (RNS) as it is a general press release announcing corporate activity to the market, which is the fallback for non-specific announcements.
2009-09-18 English
PHARMING PROVIDES UPDATE ON OUTSTANDING NUMBER OF SHARES
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release titled "PHARMING PROVIDES UPDATE ON OUTSTANDING NUMBER OF SHARES." It explicitly states that following transactions under an Equity Distribution Agreement, the company issued 1,852,230 ordinary shares for € 1.0 million, resulting in a new total outstanding share count of 115,788,785. This content directly relates to changes in the company's capital structure via share issuance/transactions, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, or potentially 'Transaction in Own Shares' (POS). Since the transaction involves the issuance of new shares for cash consideration under an agreement, SHA is the most precise fit as it covers capital structure changes resulting from share issuance. The document length is short (1866 chars), but it is the primary announcement itself, not an announcement *about* another report, so RPA/RNS is not the primary choice.
2009-09-11 English
PHARMING SUBMITS MARKETING AUTHORISATION APPLICATION FOR RHUCIN® TO THE EMEA
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Pharming Group NV has submitted a Marketing Authorisation Application (MAA) for its drug Rhucin to the European Medicines Agency (EMEA). This is a specific corporate announcement regarding regulatory submission progress, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). It details the submission, the data included, and the next steps in the regulatory process. Since there is no specific category for 'Regulatory Submission Announcement' and it is a formal announcement of a significant corporate/regulatory event, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific regulatory news that isn't a standard financial report or a specific insider/dividend action. Given the length and content, it is not a simple RPA.
2009-09-03 English
Pharming gives update on outstanding number of shares
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "PHARMING GIVES UPDATE ON OUTSTANDING NUMBER OF SHARES." It explicitly details the issuance of 773,568 ordinary shares following a transaction under a Standby Equity Distribution Agreement (SEDA) and states the resulting total number of outstanding ordinary shares (113,936,555). This content directly relates to changes in the company's capital structure through the issuance of shares, which aligns precisely with the definition of 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP) but a specific report on the resulting share count after an issuance.
2009-08-28 English
FDA approves Investigational New Drug application for Prodarsan® in Cockayne Syndrome patients
Regulatory Filings Classification · 98% confidence The document is a press release dated August 14, 2009, announcing that the FDA accepted an Investigational New Drug (IND) application for Prodarsan®. It details the upcoming clinical trial, background on the disease (Cockayne Syndrome), and the product's development status. This type of announcement, focusing on regulatory milestones (IND acceptance) and clinical trial initiation, is characteristic of an announcement related to drug development progress. It is not a full Annual Report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about a regulatory step in drug development, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate/regulatory update that doesn't match the other specific financial or governance codes. It is too detailed to be a simple Report Publication Announcement (RPA).
2009-08-14 English
Pharming announces financial results first half year 2009
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive financial report for the first half of 2009 (HY1 2009). It contains detailed financial statements (Statement of financial position, Statement of income, Statement of cash flows), share data, and a management discussion and analysis of the financial results. Although it is titled as a press release at the beginning, the content includes the full 'Interim Report of the Board of Management' and provides substantive financial data, meeting the criteria for an Interim/Quarterly Report (IR) rather than just an earnings release or announcement. H1 2009
2009-07-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.